A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

June 28, 2011

Norvir-Free Boosted Prezista Tablet in the Works

Tibotec Therapeutics—the research and development division of Janssen Pharmaceuticals—has entered an agreement with Gilead Sciences to develop a fixed-dose combination (FDC) tablet containing its protease inhibitor Prezista (darunavir) and Gilead Sciences’ experimental boosting agent cobicistat, according to a Janssen announcement.

During the past decade, a number of different HIV drugs have been combined into single pills, both to reduce the total number of pills that people with HIV take and to extend the rights of companies to exclusively sell their drugs. The most successful of these combinations, Atripla—which contains Bristol-Myers Squibb’s Sustiva (efavirenz) and Gilead’s Truvada (tenofovir plus emtricitabine)—was the first to combine drugs from two different companies.

Aside from Kaletra, which combines Abbott Laboratories’ lopinavir and ritonavir, there are no other protease inhibitors (PIs) co-formulated with other necessary agents designed to minimize dosing requirements while at the same time boosting effectiveness. With Gilead developing an agent, cobicistat, that can be used as an alternative to Norvir (ritonavir) to boost blood levels of other PIs, some PI manufacturers have expressed interest in partnering with Gilead to develop co-formulated products that can further minimize daily pill counts.  

“We are excited to be able to study and develop Prezista with an alternative boosting agent in a combination product which has the potential to reduce the number of tablets patients take,” said Johan Van Hoof, MD, of Janssen. “Prezista is one of the leading protease inhibitors, and co-formulating it with cobicistat in a new combination product demonstrates our commitment to HIV and innovations that will provide new options for patients.”

The deal to combine Prezista with cobicistat will depend on two criteria. First, the U.S. Food and Drug Administration (FDA) must approve cobicistat. This approval is anticipated sometime within the next year. The second, according to Janssen, is that negotiations between it and Gilead on another FDC tablet must also be complete.

This other FDC will combine Prezista and cobicistat with Gilead’s Emtriva (emtricitabine) and another Gilead drug that is in early stage testing. That drug, GS-7340, requires much lower doses than Viread and is expected to remain in the body for a long time before it is eliminated. This would make it ideal to combine with other drugs.

Janssen said it will have full rights and responsibilities for manufacturing and marketing the FDC of Prezista and cobicistat, while Gilead will take full responsibility for manufacturing and marketing the FDC of four drugs.

Search: Prezista, darunavir, Norvir, ritonavir, cobicistat, GS-7340, Emtriva, emtricitabine, tenofovir, Viread, Atripla, Truvada, booster, Jannsen, Tibotec Therapeutics, Gilead Sciences, fixed dose combination


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter


Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.